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Introduction {#sec004}
============

Natural death defines the death primarily attributed to an illness or an internal malfunction of the body, and not directly influenced by external forces. The forensic pathologists can straightforwardly identify the cause of natural death when macroscopic investigations are conclusive \[[@pone.0167358.ref001]\]. However, when a macroscopic cause is not evident, the final identification of causality can become tedious and complicated. Despite comprehensive macroscopic, microscopic as well as toxicological investigation, around 5%-10% of cases will remain unexplained and will be classified as sudden unexpected deaths (SUD), often defined in the report as *death from a supposed arrhythmia* \[[@pone.0167358.ref002], [@pone.0167358.ref003]\]. In the young population, this percentage may increase up to 30%-50% \[[@pone.0167358.ref004]--[@pone.0167358.ref006]\]. Even if the cause of death remains unanswered after a thorough forensic investigation, the legal work is usually concluded. However, from the medical standpoint, an unidentified etiology conveys dangerous clinical implications; these unexplained deaths may be caused by an inherited cardiac disease, which potentially leaves family members at risk.

In a simplistic classification, deaths caused by cardiac genetic alterations may affect two different disease groups, channelopathies and cardiomyopathies \[[@pone.0167358.ref007]\]. It is estimated that 10% to 25% of SUD in the adult, and up to one-third in infantile and juvenile SUD, may be explained by cardiac channelopathies \[[@pone.0167358.ref008]--[@pone.0167358.ref011]\]. These channelopathies include mainly Long QT syndrome (LQTS), Short QT syndrome (SQTS), Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT), and Brugada syndrome (BrS) \[[@pone.0167358.ref012]\]. In addition, pathogenic variations in genes encoding structural proteins are responsible for cardiomyopathies (Hypertrophic Cardiomyopathy (HCM), Dilated Cardiomyopathy (DCM), and Arrhythmogenic Cardiomyopathy (AC), among others). These cardiomyopathies will usually present anatomo-morphological changes in the cardiac tissue, which can be diagnosed at autopsy \[[@pone.0167358.ref013]\], but recent reports have suggested that in infants they could also be potentially responsible for sudden death in the structurally normal heart \[[@pone.0167358.ref014], [@pone.0167358.ref015]\].

Because SUD may be the first manifestation of an unknown inherited cardiac disease, the use of genetic testing, the so-called molecular autopsy, could be determinant in the discovery of causality, in the identification of genetic carriers in family members, and in the further adoption of preventive strategies \[[@pone.0167358.ref016], [@pone.0167358.ref017]\]. Despite that current forensic guidelines recommend molecular autopsy as part of routine protocol in SUD cases, this is seldom performed\[[@pone.0167358.ref018], [@pone.0167358.ref019]\]. This molecular investigation has been mainly limited to research projects, and usually constrained to the analysis of the most prevalent genes associated with channelopathies *(KCNQ1*, *KCNH2*, *SCN5A* and *RYR2)*, leaving several potential candidate genes untested \[[@pone.0167358.ref020], [@pone.0167358.ref021]\]. With the advent of high-throughput genetic technologies, Next Generation Sequencing (NGS), massive genetic sequencing has become available \[[@pone.0167358.ref022]\]. Recent reports have shown that NGS analysis could become an important asset in post-mortem examination \[[@pone.0167358.ref023]--[@pone.0167358.ref027]\]. To date, only one comprehensive study has been performed to prove the value of genetic testing in natural death \[[@pone.0167358.ref028]\].

In the present work we have addressed this issue by performing a prospective full epidemiological analysis of sudden death in a correlative cohort of SUD victims younger than 50 years of age, referred for forensic investigation due to out of hospital natural death. The goal was to define the etiology of natural death in the young, and to investigate whether genetic defects could contribute to this event. To perform the genetic analysis we have taken advantage of a custom-made resequencing panel. By including molecular diagnostic strategies, the ultimate goal of this work has been to develop a decision algorithm to better refine the forensic investigation, to assess the value of this powerful diagnostic tool in detecting a potential etiology, and to define which families would benefit from further clinical and genetic investigation.

Methods {#sec005}
=======

Our project was initiated in 2012, in collaboration with Institut de Medicina Legal i Ciències Forenses de Catalunya (IMLCFC). The IMLCFC oversees and concentrates all SUD cases, which require forensic investigation. We have focused the project in those cases investigated by the pathologists in the Catalonia area (population of 7.5 million people).

Forensic analysis {#sec006}
-----------------

The study was approved by the ethics committee of our Hospital, and follows the Helsinki II declaration. Our inclusion criteria were victims of sudden death, from natural cause, younger than 50 years of age. A complete autopsy examination was performed according to current international regulations \[[@pone.0167358.ref001], [@pone.0167358.ref018]\]. When the macroscopic autopsy was labelled as negative, the forensic pathologists performed complete histological and toxicological investigation, and collected a blood sample for genetic investigation. We excluded those cases in which the autopsy was labelled as violent death, including death from drug overdose.

DNA sample {#sec007}
----------

Genomic DNA was extracted with Chemagic MSM I from post-mortem whole blood (Chemagic human blood). DNA was checked in order to assure quality (Absorbance 260/280:260/230 should be a minimum 1.8: 2.2 respectively), and was quantified before processing with the NGS strategy. Spectrophotometric measurements were performed to assess quality ratios of absorbance; DNA concentration was determined by fluorometry (Qubit, Life Technologies). DNA integrity was assessed on a 0.8% agarose gel.

NGS sample preparation {#sec008}
----------------------

The DNA was fragmented (Bioruptor, Diagenode). Library preparation was performed according to the manufacturer's instructions (SureSelect XT Custom 0.5--2.9Mb library, Agilent Technologies, Inc). After capture, indexed libraries were sequenced in six-sample pools per cartridge. Paired-end sequencing process was developed on MiSeq System (Illumina) using 2x150 bp reads length.

Custom Resequencing panel {#sec009}
-------------------------

Those samples with a good DNA quality were investigated using a custom-made genetic panel, which included 55 genes associated with SCD (*ACTC1*, *ACTN2*, *ANK2*, *CACNA1C*, *CACNB2*, *CASQ2*, *CAV3*, *CRYAB*, *CSRP3*, *DES*, *DMD*, *DSC2*, *DSG2*, *DSP*, *EMD*, *FBN1*, *GLA*, *GPD1L*, *HCN4*, *JPH2*, *JUP*, *KCNE1*, *KCNE2*, *KCNH2*, *KCNJ2*, *KCNQ1*, *LAMP2*, *LDB3*, *LMNA*, *MYBPC3*, *MYH6*, *MYH7*, *MYL2*, *MYL3*, *MYOZ2*, *PDLIM3*, *PKP2*, *PLN*, *PRKAG2*, *RYR2*, *SCN4B*, *SCN5A*, *SGCA*, *SGCB*, *SGCD*, *TAZ*, *TCAP*, *TGFB3*, *TGFBR2*, *TNNC1*, *TNNI3*, *TNNT2*, *TPM1*, *TTN*, and *VCL*). The panel also included structural proteins, as some recent publications have suggested that variants in these genes may be associated with SCD, even in the structurally normal heart \[[@pone.0167358.ref011]\]. All gene isoforms described in Ensembl 75 (<http://www.ensembl.org/>) which have been linked at least with either a RefSeq code (<http://www.ncbi.nlm.nih.gov/refseq/>) or CCDS (<https://www.ncbi.nlm.nih.gov/CCDS/>) were included. Coordinates of sequence data were based on UCSC human genome version hg19 (NCBI GRCh37 built). Biotinylated cRNA probe solution was used as a capture probe (Agilent Technologies). Probes were designed using eArray (Agilent Technologies) and the design was optimized by Gendiag.exe S.L. The gene panel final size was 432,512kbp. This custom enrichment gene design is commercialized by Ferrer inCode as SudD inCode®.

Sanger sequencing {#sec010}
-----------------

Sanger sequencing was used to confirm non-common (Minor Allele Frequency--MAF- \< 1%) genetic variants detected by NGS, as well as in the genetic analysis of those cases with poor DNA quality. In this situation, we limited the analysis to the guideline recommended genes (*SCN5A* -NM_198056-, *KCNQ1* -NM_000218-, *KCNH2* -NM_000238-, *KCNE1* -NM_000219-, *KCNE2* -NM_172201-, and *RyR2* -NM_001035-) \[[@pone.0167358.ref029], [@pone.0167358.ref030]\]. The exons and exon-intron boundaries of each gene were amplified (Verities PCR, Applied Biosystems, Austin, TX, USA), the PCR products were purified (Exosap-IT, Affymetrix, Inc. USB® Products, Cleveland, OH, USA) and they were directly sequenced in both directions (Big Dye Terminator v3.1 and 3130XL Genetic Analyzer, both from Applied Biosystems) with posterior SeqScape Software v2.5 (Life Technologies) analysis, comparing obtained results with the reference sequence from hg19. The identified variations were compared with DNA sequences from 300 healthy Spanish individuals (individuals not related to any patient and of the same ethnicity; 600 alleles), as control cases, and contrasted with Human Gene Mutation Database -HGMD- (<http://www.hgmd.cf.ac.uk/ac/index.php>), HapMap (<http://hapmap.ncbi.nlm.nih.gov/>), 1000 genomes project (<http://www.1000genomes.org/>), Exome Aggregation Consortium--ExAC- (<http://exac.broadinstitute.org/>), and Exome Variant Server--EVS--(<http://evs.gs.washington.edu/EVS/>). Sequence variants were described following the HGVS rules (<http://www.hgvs.org/>), and checked in Mutalyzer (<https://mutalyzer.nl/>).

Bioinformatics {#sec011}
--------------

The secondary bioinformatic analysis of the data obtained included adaptor and low quality bases trimming on FASTQ files. Trimmed reads were mapped with GEM III. The output were sorted and uniquely and properly mapped read pairs were selected. Finally, the variant calling over the cleaned BAM were performed with SAMtools v.1.2 together with an ad hoc developed script. The final annotation steps provided information included in public databases. Variants were annotated with dbSNP human build 142 IDs (<http://www.ncbi.nlm.nih.gov/SNP/>); the 1000 Genomes browser Phase 3 (<http://www.1000genomes.org/>); the Exome Aggregation Consortium (ExAC) v.0.3 (<http://exac.broadinstitute.org/>); NHLBI Exome Sequencing Project (ESP) ESP6500SI-V2 (<http://evs.gs.washington.edu/EVS/>); Ensembl information and in-home database IDs, if available. The Human Gene Mutation Database (HGMD, <http://www.hgmd.cf.ac.uk/ac/index.php>) was also consulted to identify previously reported pathogenic mutations. In silico prediction of pathogenicity of novel genetic variations was assessed in CONDEL software (CONsensus DELeteriousness scores of missense SNVs) (<http://bg.upf.edu/condel/>), Mutation Taster (<http://www.mutationtaster.org/>), and PROVEAN (Protein Variation Effect Analyzer) (<http://provean.jcvi.org/index.php>). Alignment of DNA sequences for different species was also performed for these novel variations using UniProt database (<http://www.uniprot.org/>).

Assessment of pathogenicity {#sec012}
---------------------------

The rare variants (MAF \< 1%) were classified according recent ACMG guidelines \[[@pone.0167358.ref031]\], following the criteria:

Likely/probably benign variants (PBV):

-   Variants already described in any of databases, with all in-silico models predicted neutrality.

Variants of uncertain/unknown significance (VUS):

-   Novel variants and all in-silico models predicted neutrality or differed between predictions.

-   Variants already described in any of databases, and in-silico models differed between predictions.

Likely/probably pathogenic variants (PPV):

-   Likely pathogenic variants reported to be disease-causing but where the author has indicated that there may be some degree of doubt, or subsequent evidence has come to light in the literature.

-   Radical variants (insertions, deletions or premature stop codons)

-   Splice site variants between ± 5 nucleotides, and all in-silico models consulted predicted pathogenicity.

-   Novel variants with all in-silico models predicting pathogenicity.

Disease causing mutations (DM):

-   Variants already reported to be disease-causing.

Results {#sec013}
=======

This is a three-year prospective study that was started on February 2012. We have collected a total of 789 consecutive cases -609 males (77.19%) and 180 females (22.81%)-. The range of age is from 0 to 50 years of age (average 38.6±12.2 years old). The average age is 39.3±11.2 years in males and 36.2±14.9 years in females. In order to classify the cases, we have divided the cohort in groups of 10 years (0--10, 11--20, 21--30, 31--40, 41--50 years old).

Prevalence of natural death according to age {#sec014}
--------------------------------------------

In our cohort, most cases were between 41 and 50 years of age (467 out of 789, 59.19%). A total of 190 cases (24.08%) were between 31--40 years old and 132 cases (16.73%) were below age 30. Regarding gender differences, the number of males was higher in all ranges of age, showing most differences after age 30, with males nearing 80% of cases ([Fig 1](#pone.0167358.g001){ref-type="fig"}).

![Percentage of natural death according to age and gender.\
The main percentage of death occurs in last range of ages. In all ranges of age, males are a high percentage of death. Males are indicated in black color. Females are indicated in white color.](pone.0167358.g001){#pone.0167358.g001}

Context in which the natural death took place {#sec015}
---------------------------------------------

Deaths were classified depending whether they took place during stress/exercise, during sleep, or during routine daily activities. Information about the context of death was provided in 532 cases. The majority of deaths occurred during routine daily activities (376 cases, 70.68%), 98 occurred during sleep (18.42%) and 58 during exercise (10.90%). Deaths during sleep and during exercise were more common before the age of 20 ([Fig 2](#pone.0167358.g002){ref-type="fig"}).

![Context of death.\
The daily activities had a higher prevalence in cases higher 30 years old. Daily activities are indicated in black color. Sleep is indicated in white color. Exercise/Stress is indicated in grey color.](pone.0167358.g002){#pone.0167358.g002}

Etiology of death {#sec016}
-----------------

Concerning the cause of death, the forensic pathologist directly determined a conclusive cause of death after macroscopic evaluation (positive macroscopic autopsy) in 506 cases (64.13%), while a yet inconclusive autopsy (negative macroscopic autopsy) was reported in the remaining cases. Most macroscopically positive cases were males (383 cases, 75.69%). Regarding negative autopsy cases, most of these cases were also males (226 cases, 79.86%).

Positive macroscopic autopsy {#sec017}
----------------------------

Out of the 506 cases, the macroscopic investigation defined the following causes of death: cardiac in 230 cases (45.45%)--mainly coronary artery disease (127 cases)-; vascular (embolism or hemorrhage) in 137 cases (27.08%); pulmonary/respiratory in 91 cases (17.98%) -infectious process being responsible for the death in 47 cases, and digestive in 21 cases-; finally, 27 cases (5.34%), had other less common findings which included 8 non-vascular neurological, 7 carcinogenic, 6 endocrinologic, 2 obstetric, 1 infectious and 3 multiorganic failure.

Negative macroscopic autopsy. Microscopic analyses {#sec018}
--------------------------------------------------

The macroscopic autopsy was not able to detect the cause of death in 283 cases (35.87%) and these were labeled as macroscopically negative. To identify a potential cause of death, these cases were further investigated with histological analysis. This investigation was able to refine the potential cause of death into the following subgroups: 1) Cardiac, which included coronary disease in 98 cases (34.63%) (presence of thrombus, of myocardial infarction or of severe coronary stenosis \>75%), and 36 (12.72%) potentially cardiac inherited cases, by histological identification of cardiomyopathy; and, 2) unexplained cases, which included 149 (52.65%) cases with microscopic findings showing no histological alterations). Among these 149 cases, there were 23 cases (15.44%) in which death occurred before the first year of age, thus they were labeled as sudden infant death syndrome (SIDS).

Natural death according to context and final autopsy results {#sec019}
------------------------------------------------------------

With further inclusion of histological analysis, 364 out of 789 cases (46%) were definitively labeled as deaths from a cardiac origin. This percentage is underrepresented, as it did not include the 149 negative cases, some of whom presumably died also from cardiac causes. Stress/exercise related death was more frequent in cardiac cases (51.72%), while deaths during daily activity were more prevalent in vascular (20.23%), as well as pulmonary (12.84%) etiologies ([Fig 3](#pone.0167358.g003){ref-type="fig"}).

![Cause of death according to context of death.\
The distribution showed that cardiac causes were more prevalent in the context of stress/exercise, while vascular were more prevalent during daily activities. The unexplained cases had a higher presence in context of sleep and stress/exercise. Daily activities are indicated in black color. Sleep is indicated in white color. Exercise/Stress is indicated in grey color.](pone.0167358.g003){#pone.0167358.g003}

Natural Death according to age groups {#sec020}
-------------------------------------

We have divided the results in five groups of age ([Fig 4](#pone.0167358.g004){ref-type="fig"}):

![Cause of death distributed according to age.\
There is an increase of cardiac causes with age, reaching 54% of cases in the older group of age. However the unexplained cases were common in young below 30 years old, reaching the 66% of cases in youngest group of age. Cardiac is indicated in black color. Vascular is indicated in white color. Pulmonary is indicated in grey color. Unexplained is indicated in vertical lines of grey color. Other causes are indicated in horizontal lines of grey color.](pone.0167358.g004){#pone.0167358.g004}

### 0--10 years old cohort {#sec021}

This sub-group included a total of 50 cases (6.34%). Of them, 7 cases (14%) died of cardiac causes (2 DCM, 2 myocarditis, 1 LQTS, 2 cardiac cause not specified), 1 case (2%) of neurological vascular causes, 5 cases (10%) of respiratory affectations (2 infectious, 1 aspiration, 1 asthmatic and 1 obstructive), 3 cases (6%) of cerebral/neurological (2 infectious and 1 malformation), and 1 case (2%) died still birth. Finally, 33 cases (66%) were left unexplained (23 SIDS and 1 SUDEP) after complete autopsy.

### 11--20 years old cohort {#sec022}

This sub-group included 20 cases (2.53%). Of them, 4 (20%) died of cardiac causes (1 HCM, 1 DCM, 1 Congenital and 1 myocarditis), 4 (20%) of vascular causes (3 pulmonary and 1 digestive injuries), 2 (10%) of respiratory affectations (infectious), 1 (5%) of cerebral/neurological edema, and 2 (10%) of other causes (1 digestive and 1 endocrinology). Finally, 7 (35%) cases remained unexplained.

### 21--30 years old cohort {#sec023}

This sub-group included 62 samples (7.86%). A total of 19 (30.65%) died of cardiac causes (6 coronary, 5 HCM, 1 DCM, 2 AC, 1 myocarditis, 1 congenital, 1 transplant, 1 valvular and 1 cardiac cause not specified), 9 (14.52%) of vascular injuries (5 pulmonary, 1 aortic, 2 neurological and 1 digestive injuries), 10 (16.13%) of respiratory affectations (4 infection, 3 edema, 2 aspiration and 1 asthmatic), 1 (1.61%) of cerebral/neurological pathologies (infection), and 1 (1.61%) of other causes (carcinogenic). Finally, 22 (35.48%) cases were unexplained.

### 31--40 years old cohort {#sec024}

This included 190 samples (24.08%). Of them, 82 (43.16%) died of cardiac causes (49 coronary, 11 cardiac causes not specified, 6 DCM, 8 HCM, 1 AC, 3 myocarditis, 2 congenital and 2 fibrosis), 38 (20%) of vascular injuries (15 pulmonary, 9 neurological, 8 aortic and 6 digestive), 28 (14.74%) of respiratory affectations (12 infectious, 7 edema, 3 aspiration, 2 asthmatic and 4 obstructive), 3 (1.58%) of cerebral/neurological pathologies (2 infectious and 1 edema), and 8 (4.21%) of other causes (3 digestive, 4 carcinogenic and 1 multiorganic failure). Finally, 31 (16.32%) cases were unexplained.

### 41--50 years old cohort {#sec025}

This included 467 samples (59.19%). Of them, 252 (53.96%) died of cardiac causes (171 coronary, 24 cardiac causes not specified, 18 DCM, 34 HCM, 2 AC, 2 Valvular, 1 pericarditis), 85 (18.20%) of vascular injuries (31 pulmonary, 28 digestive, 19 neurological, and 7 aortic), 46 (9.85%) of respiratory affectations (27 infectious, 10 edema, 6 obstructive, 1 asthmatic, 1 aspiration, and 1 hemorrhagic), and 28 (5.99%) of other causes (17 digestive, 7 carcinogenic, 1 endocrine, 1 multiorganic failure, 1 obstetric and 1 renal infectious causes). Finally, 56 (11.99%) cases were unexplained.

Molecular autopsy {#sec026}
-----------------

In addition to defining the etiology of natural death in our cohort, we wanted to assess whether the use of genetics could improve diagnosis ascertainment, and could better define which, if any, family members should undergo clinical/genetic evaluation. Thus, we focused our efforts in those forensic cases with potentially inherited disease or with negative microscopic autopsy:

Potentially inherited subgroup {#sec027}
------------------------------

This study was limited to cases previously considered macroscopically negative by the forensic pathologist but identified after histological analysis. A total of 32 samples showing histological alterations associated with cardiomyopathies (10 DCM, 19 HCM, 1 AC, and 2 fibrosis)([Fig 5](#pone.0167358.g005){ref-type="fig"}) were screened by NGS method. The genetic screening identified a total of 62 rare variants in 25 out of 32 samples (78.13%). Twelve variants (19.35%) were novel. All cases carried at least one variant in genes codifying for structural proteins. However, 10 cases carried at least one additional rare variant in genes encoding proteins associated with ion channels or associated proteins. According to our classification criteria, 2 variants (3.23%) were considered PBV, 39 (62.90%) VUS, 12 (19.35%) PPV, and 9 (14.52%) DM ([Table 1](#pone.0167358.t001){ref-type="table"}).

![Representative microscopic images of samples showing cardiomyopathy.\
Left. Hypertrophic Cardiomyopathy (Hematoxylin-Eosin, 20x); Center. Dilated Cardiomyopathy (Hematoxylin-Eosin, 20x); Right. Arrhythmogenic Cardiomyopathy (Masson's Trichrome, 10x).](pone.0167358.g005){#pone.0167358.g005}
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###### Genetic data of variants identified, 26 positive samples from the 32 cardiomyopathies.

![](pone.0167358.t001){#pone.0167358.t001g}

  Range    ID   Proc.   Age   Gender   Autopsy    Gene        Nucleotide            Variant             dbSNP         MAF                    ExAC %      HGMD        Classification   Disease   PPH2       Provean       Mut. Taster
  -------- ---- ------- ----- -------- ---------- ----------- --------------------- ------------------- ------------- ---------------------- ----------- ----------- ---------------- --------- ---------- ------------- -----------------
  11--20   1    NGS     17    M        HCM        *TNNI3*     c.611G\>A             p.R204H             ---           ---                    ---         CM050764    DM               HCM       Damaging   Deleterious   Disease causing
  11--20   2    NGS     19    M        DCM        *JUP*       c.56C\>T              p.T19I              rs570878629   ---                    0.01139     CM098198    PPV              ARVC      Damaging   Deleterious   Disease causing
  11--20   2                                      *VCL*       c.2046A\>T            p.L682F             rs565398652   ---                    0.006589    ---         VUS              ---       Damaging   Neutral       Disease causing
  11--20   2                                      *TTN*       c.81269T\>C           p.I27090T           rs750026544   ---                    0.003331    ---         PBV              ---       Benign     Neutral       Polymorphism
  11--20   2                                      *TTN*       c.26041A\>G           p.I8681V            ---           ---                    ---         ---         VUS              ---       Damaging   Neutral       Disease causing
  21--30   3    NGS     26    M        HCM        *SCN5A*     c.569G\>A             p.R190Q             rs199473069   ---                    0.01131     CM077628    DM               LQTS      Damaging   Deleterious   Disease causing
  21--30   4    NGS     26    M        HCM        *MYBPC3*    c.1505G\>A            p.R502Q             rs397515907   ---                    ---         CM981325    DM               HCM       Damaging   Deleterious   Disease causing
  21--30   5    NGS     29    M        HCM        *TTN*       c.14818G\>A           p.A4940T            rs72648947    0.0722/0/0.0493        0.04558     ---         VUS              ---       Damaging   Neutral       Tolerated
  21--30   5                                      *TTN*       c.17441G\>A           p.G5814D            rs72648964    0.1332/0.6309/0.2741   0.1708      ---         VUS              ---       Damaging   Neutral       Tolerated
  21--30   5                                      *TTN*       c.47849A\>G           p.K15950R           rs72646823    0.1332/0.359/0.2057    0.1372      ---         VUS              ---       Damaging   Neutral       Tolerated
  21--30   6    NGS     30    M        HCM        *PKP2*      c.184C\>A             p.Q62K              rs199601548   0.0358/0.0/0.0238      0.01679     CM061171    DM               ARVC      Damaging   Neutral       Disease causing
  21--30   6                                      *MYBPC3*    c.1598A\>G            p.Q533R             ---           ---                    ---         ---         VUS              ---       Benign     Neutral       Disease causing
  21--30   6                                      *FBN1*      c.3058A\>G            p.T1020A            rs111801777   0.0349/0.0/0.0231      0.04632     CM010035    PPV              Marfan    Benign     Neutral       Polymorphism
  21--30   6                                      *TTN*       c.85109G\>C           p.R28370T           ---           ---                    ---         ---         PPV              ---       Damaging   Deleterious   Disease causing
  31--40   7    NGS     31    M        Fibrosis   *ANK2*      c.11326A\>G           p.T3776A            rs746620876   ---                    ---         ---         VUS              ---       ---        Neutral       Polymorphism
  31--40   7                                      *TTN*       c.90538C\>T           p.R30180C           rs72648272    0.4066/0.0495/0.2902   0.4045      ---         VUS              ---       Damaging   Deleterious   Disease causing
  31--40   7                                      *TTN*       c.26542C\>T           p.H8848Y            rs72650011    0.4067/0.0745/0.2987   0.4143      CM116750    DM               ARVC      Benign     Deleterious   Polymorphism
  31--40   7                                      *TTN*       c.9359G\>A            p.R3120Q            rs72647894    0.4419/0.0908/0.3229   0.4396      ---         VUS              ---       Damaging   Neutral       Polymorphism
  31--40   8    NGS     31    M        Fibrosis   *ANK2*      c.9185A\>G            p.E3062G            ---           ---                    ---         ---         PPV              ---       Damaging   Deleterious   Disease causing
  31--40   8                                      *TTN*       c.100184delA          p.K3395fs           rs281864930   ---                    ---         ---         PPV              ---       ---        ---           Disease causing
  31--40   9    NGS     37    M        HCM        *SCN5A*     c.1127G\>A            p.R376H             rs199473101   0.0119/0/0.008         ---         CM054856    PPV              BrS       Damaging   Neutral       Disease causing
  31--40   9                                      *TNNT2*     c.101C\>T             p.A34V              ---           ---                    0.0008242   ---         VUS              ---       ---        Neutral       Polymorphism
  31--40   9                                      *TTN*       c.89795C\>A           p.P29932H           ---           ---                    ---         ---         PPV              ---       Damaging   Deleterious   Disease causing
  31--40   9                                      *TTN*       c.46610G\>A           p.R15537H           ---           ---                    0.001666    ---         VUS              ---       Damaging   Deleterious   Disease causing
  31--40   10   NGS     38    M        DCM        *ACTN2*     c.1984C\>T            p.R662W             rs150021739   0.0/0.0227/0.0077      0.004943    ---         VUS              ---       Damaging   Deleterious   Disease causing
  31--40   11   NGS     38    M        HCM        *MYBPC3*    c.2539_2549delinG     p.Y847_N850delinD   ---           ---                    ---         ---         PPV              ---       ---        ---           ---
  31--40   11                                     *TTN*       c.34372G\>C           p.V11458L           ---           ---                    ---         ---         VUS              ---       Damaging   Neutral       Disease causing
  31--40   12   NGS     39    M        HCM        *DSG2*      c.3175T\>A            p.S1059T            rs201786158   ---                    0.02816     CM071712    DM               ARVC      Damaging   Neutral       Polymorphism
  31--40   12                                     *MYBPC3*    c.103C\>T             p.R35W              ---           ---                    0.005626    CM0910203   DM               HCM       Damaging   Deleterious   Disease causing
  31--40   12                                     *TTN*       c.15625G\>A           p.G5209S            rs374964612   0.0121/0.0/0.0083      0.005090    ---         VUS              ---       Damaging   Deleterious   Disease causing
  31--40   13   NGS     40    M        HCM        *TTN*       c.76559G\>A           p.S25520N           rs200450022   0.085/0.0/0.0583       0.05921     ---         VUS              ---       Bening     Neutral       Disease causing
  31--40   13                                     *TTN*       c.17066G\>C           p.G5689A            rs200118743   0.0843/0.0/0.0574      0.08920     ---         VUS              ---       Bening     Neutral       Disease causing
  41--50   14   NGS     41    M        DCM        *MYBPC3*    c.2177C\>T            p.R726C             ---           ---                    0.003633    CM092563    DM               HCM       Damaging   Deleterious   Disease causing
  41--50   14                                     *HCN4*      c.2800C\>T            p.R934C             rs199638465   0.0133/0/0.0088        0.06047     ---         VUS              ---       Damaging   Neutral       Disease causing
  41--50   15   NGS     41    M        DCM        *DSP*       c.6497G\>A            p.R2166Q            ---           ---                    0.0008244   ---         VUS              ---       Benign     Neutral       Polymorphism
  41--50   15                                     *TTN*       c.47501T\>G           p.I15834S           rs776899398   ---                    0.0008312   ---         VUS              ---       Damaging   Deleterious   Disease causing
  41--50   15                                     *TTN*       c.4208G\>C            p.R1403T            rs531590921   ---                    0.03321     ---         VUS              ---       Damaging   Deleterious   Disease causing
  41--50   16   NGS     44    M        HCM        *CSRP3*     c.10T\>C              p.W4R               rs45550635    0.5358/0.0455/0.3697   0.237       CM023060    DM               DCM       Damaging   Deleterious   Disease causing
  41--50   16                                     *HCN4*      c.2730C\>A            p.F910L             rs200814534   0.0123/0.0/0.0081      0.01675     ---         VUS              ---       Benign     Neutral       Disease causing
  41--50   17   NGS     45    M        HCM        *ANK2*      c.10948G\>C           p.E3650Q            ---           ---                    0.001649    ---         VUS              ---       Benign     Neutral       Disease causing
  41--50   17                                     *TTN*       c.19570G\>A           p.D6524N            rs72648973    0.1463/0.0539/0.1175   0.07463     ---         VUS              ---       Damaging   Deleterious   Disease causing
  41--50   17                                     *TTN*       c.41023C\>T           p.P13675S           rs72677242    0.3262/0.0258/0.2305   0.5239      ---         VUS              ---       Benign     Deleterious   Disease causing
  41--50   17                                     *TTN*       c.10966G\>A           p.A3656T            rs72648923    0.3282/0.0267/0.2339   0.3419      ---         VUS              ---       Damaging   Neutral       Disease causing
  41--50   18   NGS     45    H        HCM        *TTN*       c.62584G\>A           p.V20862I           rs549709481   ---                    0.002488    ---         VUS              ---       Damaging   Neutral       Disease causing
  41--50   18                                     *TTN*       c.289G\>A             p.V97M              rs185921345   0.0349/0.0227/0.0308   0.2084      ---         VUS              ---       Damaging   Neutral       Disease causing
  41--50   19   NGS     46    M        DCM        *TTN*       c.23131A\>G           p.I7711V            rs72648994    0.0486/0.0524/0.0498   0.43        ---         VUS              ---       Damaging   Neutral       Polymorphism
  41--50   19                                     *TTN*       c.67191A\>C           p.Q22397H           rs201512527   0.1936/0.0262/0.1406   0.09869     ---         VUS              ---       Damaging   Neutral       Polymorphism
  41--50   19                                     *TTN*       c.95443G\>C           p.E31815Q           rs148525155   0.0603/0.512/0.0574    0.3337      ---         VUS              ---       Benign     Deleterious   Disease causing
  41--50   20   NGS     46    M        HCM        *TTN*       c.96220-96222delCCT   p.P32074del         ---           ---                    ---         ---         PPV              ---       ---        Deleterious   Disease causing
  41--50   21   NGS     46    M        HCM        *RYR2*      c.649A\>G             p.I217V             rs200642525   0.0362/0.0/0.0246      0.01408     CM125874    PPV              LQTS      Benign     Neutral       Disease causing
  41--50   21                                     *TTN*       c.61160G\>C           p.G20387A           rs201381085   0.0366/0.0/0.0252      0.02398     ---         VUS              ---       Damaging   Deleterious   Disease causing
  41--50   22   NGS     47    F        DCM        *ANK2*      c.2048A\>G            p.D683G             ---           ---                    ---         ---         VUS              ---       Benign     Neutral       Polymorphism
  41--50   22                                     *RYR2*      c.3380A\>G            p.E1127G            rs200525962   0.0832/0.0/0.0556      ---         ---         VUS              ---       Damaging   Deleterious   Disease causing
  41--50   22                                     *DMD*       c.8555A\>G            p.K2852R            ---           ---                    0.001181    ---         VUS              ---       Benign     Neutral       Disease causing
  41--50   22                                     *VCL*       c.1907A\>G            p.H636R             rs71579374    0.1279/0.0227/0.0923   0.1492      ---         VUS              ---       Damaging   Deleterious   Disease causing
  41--50   23   NGS     48    M        HCM        *TTN*       c.30760-30762delGAA   p.E10254del         ---           ---                    ---         ---         PPV              ---       ---        Deleterious   Polymorphism
  41--50   24   NGS     49    M        HCM        *PKP2*      c.1468C\>T            p.R490W             rs149930872   0.0233/0.159/0.0693    0.06146     ---         VUS              ---       Damaging   Neutral       Polymorphism
  41--50   25   NGS     49    F        HCM        *PKP2*      c.712G\>T             p.G269R             ---           ---                    0.0008264   ---         VUS              ---       Damaging   Neutral       Disease causing
  41--50   25                                     *CACNA1C*   c.805G\>A             p.N550S             ---           ---                    0.003790    ---         PBV              ---       Benign     Neutral       Polymorphism
  41--50   25                                     *TTN*       c.55862G\>T           p.G18621V           ---           ---                    ---         ---         PPV              ---       Damaging   Deleterious   Disease causing
  41--50   26   NGS     49    M        DCM        *ANK2*      c.158G\>C             p.G53A              ---           ---                    0.0008860   ---         VUS              ---       Damaging   Deleterious   Polymorphism
  41--50   26                                     *TTN*       c.89737G\>A           p.G29913R           rs111616037   0.0119/0.0246/0.016    0.003876    ---         VUS              ---       Damaging   Deleterious   Disease causing

NGS, Next Generation sequencing. Age is expressed in years, months (m) or days (d). Autopsy is expressed as Hypertrophy Cardiomyopathy (HCM), Dilated Cardiomyopathy (DCM) and Fibrosis. Variant nomenclature is at cDNA and Protein level. Minor Allele Frequency (MAF) is expressed as EA/AA/ALL respectively, EA (European-American)/AA (African-American)/ALL; and Minor Alelle Frequency from The Exome Aggregation Consortium (ExAC), both are expressed in percentage. Each variant is classified as Disease Mutation (DM), Probably Pathogenic Variant (PPV), Variant of Uncertain Significance (VUS) and Probably Benign Variant (PBV).

Unexplained sudden death subgroup {#sec028}
---------------------------------

The analysis was performed in 119 samples with negative results after macroscopic and histological studies.

All samples were analyzed using NGS technology except in 24 samples in which the screening was limited to Sanger sequencing due to low DNA quality. The Sanger sequencing method identified at least one rare variant in 6 out of 24 (25%) samples. On the other hand, with the use of NGS technology we identified 76 out of 95 (80%) samples carrying at least one rare variant. Concerning NGS samples, 41 of them (43.2%) carried at least one rare variant in genes encoding proteins associated with ion channels, and 64 (67.3%) carried at least one rare variant in genes codifying for structural proteins. Overall, we detected 49(41.2%) samples carrying PPV and/or DM. The genetic screening identified a total of 197 rare variants, 6 detected by Sanger method and 191 by NGS method. Thirty-six (18.27%) were novel variants. Our criteria classified 16 (8.12%) as PBV, 100 (50.76%) as VUS, 60 (30.46%) as PPV and 21 (10.66%) as DM ([Table 2](#pone.0167358.t002){ref-type="table"}).

10.1371/journal.pone.0167358.t002

###### Genetic data of variants identified, 81 positive cases from the 119 SUD cases.

![](pone.0167358.t002){#pone.0167358.t002g}

  Range    ID   Proc.   Age   Gender   Autopsy   Gene        Nucleotide            Variant       dbSNP         MAF (%)                ExAC %      HGMD        Classification   Disease                PPH2       Provean       Mut. Taster
  -------- ---- ------- ----- -------- --------- ----------- --------------------- ------------- ------------- ---------------------- ----------- ----------- ---------------- ---------------------- ---------- ------------- -----------------
  0--10    1    S       1m    F        SIDS      *SCN5A*     c.5054A\>T            p.E1685D      ---           ---                    ---         BM1492175   PPV              SCD                    Damaging   Deleterious   Disease causing
  0--10    1                                     *SCN5A*     c.5055G\>T            p.V1685V      ---           ---                    ---         CM1413453   PPV              SCD                    Damaging   Deleterious   Disease causing
  0--10    2    NGS     3d    M        SIDS      *TTN*       c.74377C\>G           p.P24793A     rs56137800    ---                    0.2859      ---         VUS              ---                    Damaging   Deleterious   Disease causing
  0--10    2                                     *TTN*       c.11446G\>A           p.V3816I      rs72648929    ---                    0.2733      ---         VUS              ---                    Damaging   Neutral       Disease causing
  0--10    3    NGS     13d   F        SIDS      *DSP*       c.5598G\>C            p.Q1866H      ---           ---                    0.0008238   ---         PBV              ---                    Benign     Neutral       Polymorphism
  0--10    3                                     *TTN*       c.74195G\>A           p.R24732H     rs55850344    0.0608/0.0528/0.0583   0.03066     ---         PBV              ---                    Benign     Neutral       Polymorphism
  0--10    4    NGS     1m    F        SIDS      *SCN5A*     c.5848G\>T            p.V1950L      rs41315493    0.0596/0.457/0.191     0.005412    CM024652    PPV              BrS                    Benign     Neutral       Polymorphism
  0--10    4                                     *DSG2*      c.1003A\>G            p.T335A       rs191564916   0.061/0.0/0.0419       0.05558     CM098196    PPV              ARVC                   Damaging   Neutral       Polymorphism
  0--10    5    NGS     41d   M        SIDS      *MYH6*      c.595G\>A             p.A199T       rs535526291   ---                    ---         ---         PPV              ---                    Damaging   Deleterious   Disease causing
  0--10    5                                     *TTN*       c.16752C\>G           p.I5584M      rs563320328   ---                    0.001668    ---         PBV              ---                    Benign     Neutral       Polymorphism
  0--10    6    NGS     2m    M        SIDS      *CACNA1C*   c.5809C\>T            p.R1937C      rs185788586   0.1437/0.1257/0.1379   0.7488      CM1413436   PPV              SCD                    Benign     Neutral       Disease causing
  0--10    7    NGS     2m    F        SIDS      *SCN5A*     c.1844G\>A            p.G615E       rs12720452    0.0595/0.0/0.0399      0.023       CM022061    PPV              LQTS-DA                Damaging   Neutral       Polymorphism
  0--10    8    NGS     3m    M        SIDS      *TTN*       c.81017G\>A           p.R27006H     rs111727915   0.0239/0.1711/0.0722   0.04143     ---         VUS              ---                    Damaging   Deleterious   Disease causing
  0--10    8                                     *TTN*       c.70109G\>C           p.W23370S     rs186681106   0.0244/0.3203/0.1171   0.05575     ---         VUS              ---                    Damaging   Deleterious   Disease causing
  0--10    8                                     *TTN*       c.64675G\>A           p.E21559K     rs149763294   0.0243/0.1318/0.0582   0.03929     ---         VUS              ---                    Damaging   Deleterious   Disease causing
  0--10    8                                     *TTN*       c.28025C\>A           p.P9342Q      rs200459347   0.0243/0.1326/0.0583   0.04174     ---         VUS              ---                    Benign     Deleterious   Polymorphism
  0--10    8                                     *TTN*       c.18047C\>A           p.S6016Y      rs187925021   0.0245/0.1609/0.0672   0.449       ---         VUS              ---                    Benign     Deleterious   Polymorphism
  0--10    8                                     *TTN*       c.17936G\>A           p.R5979H      rs138853909   0.0362/0.155/0.074     0.05243     ---         PBV              ---                    Benign     Neutral       Polymorphism
  0--10    8                                     *TTN*       c.17600T\>C           p.M5867T      rs374408615   0.012/0.0/0.0081       0.00161     ---         PBV              ---                    Benign     Neutral       Polymorphism
  0--10    9    NGS     1     F        SIDS      *DMD*       c.4529A\>G            p.K1510R      rs72468638    0.0297/0.0/0.0189      0.5399      ---         PBV              ---                    Damaging   Neutral       Polymorphism
  0--10    9                                     *PRKAG2*    c.1107-5C\>T          ---           ---           ---                    ---         ---         VUS              ---                    ---        ---           ---
  0--10    10   NGS     14m   M        U         *JUP*       c.283G\>C             p.G95R        ---           ---                    ---         ---         VUS              ---                    Benign     Neutral       Polymorphism
  0--10    11   NGS     16m   M        U         *FBN1*      c.8176C\>T            p.R2726W      rs61746008    0.1047/0.1137/0.1078   0.07331     CM950453    PPV              Marfan                 Benign     Deleterious   Disease causing
  0--10    11                                    *TNNC1*     c.304C\>A             p.R102S       ---           ---                    ---         ---         VUS              ---                    Benign     Deleterious   Disease causing
  0--10    11                                    *GPD1L*     c.520G\>A             p.E174K       rs112122950   0.1279/0.0227/0.0923   0.01483     ---         VUS              ---                    Benign     Neutral       Disease causing
  0--10    11                                    *TTN*       c.44832C\>G           p.N14944K     rs199615557   0.01279/0/0.0333       0.03031     ---         VUS              ---                    Benign     Deleterious   Disease causing
  0--10    12   NGS     18m   F        U         *CACNA1C*   c.6062G\>A            p.R2021Q      rs112414325   0.2183/0.0518/0.1652   0.3594      CM1413437   PPV              SCD                    Bening     Neutral       Disease causing
  0--10    12                                    *DSP*       c.916G\>A             p.A306T       rs368193211   0.0116/0.0/0.0077      0.004944    CM1413441   PPV              SCD                    Damaging   Neutral       Disease causing
  0--10    13   NGS     3     M        U         *DSP*       c.314G\>A             p.R105Q       ---           ---                    0.004118    CM1413443   PPV              SCD                    Damaging   Neutral       Disease causing
  0--10    13                                    *DSP*       c.946A\>G             p.M316V       rs201672777   0.0116/0/0.0077        0.002484    CM1413442   PPV              SCD                    Damaging   Deleterious   Disease causing
  0--10    13                                    *CACNB2*    c.47_49delCGG         p.A16fs       ---           ---                    ---         ---         PPV              ---                    ---        ---           Disease causing
  0--10    13                                    *DMD*       c.7183G\>A            p.A2395T      rs72466590    0.2229/0/0.142         0.07408     CM072994    DM               MD                     Benign     Neutral       Polymorphism
  0--10    13                                    *FBN1*      c.1175C\>G            p.P392R       rs534127494   ---                    0.003345    CM1413444   PPV              SCD                    Damaging   Deleterious   Disease causing
  0--10    14   NGS     3     M        SUDEP     *TTN*       c.89494C\>A           p.P29832T     rs373876117   0.0122/0.0/0.0084      0.01195     ---         VUS              ---                    Damaging   Deleterious   Disease causing
  0--10    14                                    *TTN*       c.5577G\>T            p.R1859S      ---           ---                    0.003295    BM1437281   PPV              SCD                    Damaging   Deleterious   Polymorphism
  0--10    15   NGS     3     M        U         *TTN*       c.77076A\>C           p.E25693D     ---           ---                    0.002485    ---         VUS              ---                    Benign     Neutral       Disease causing
  0--10    16   S       10    M        U         *KCNH2*     c.2674C\>T            p.R892C       rs201627778   0.0116/0.0227/0.0154   0.04794     CM1413446   PPV              SCD                    Damaging   Deleterious   Disease causing
  11--20   17   NGS     14    F        U         *DSC2*      c.1789G\>T            p.V597F       rs143040393   0.0116/0.2497/0.0923   0.01818     CM1413440   PPV              SCD                    Benign     Deleterious   Polymorphism
  11--20   17                                    *CACNA1C*   c.5809C\>T            p.R1937C      rs185788586   0.1437/0.1257/0.1379   0.7488      CM1413436   PPV              SCD                    Damaging   Neutral       Disease causing
  11--20   17                                    *ANK2*      c.7148C\>T            p.P2383L      rs35960628    0/0.0908/0.0308        0.01237     CM1413435   PPV              SCD                    Benign     Neutral       Polymorphism
  11--20   17                                    *TGFB3*     c.755-5T\>C           ---           ---           ---                    ---         ---         VUS              ---                    ---        ---           ---
  11--20   17                                    *DMD*       c.4328A\>G            p.Q1443R      ---           ---                    0.001150    CM1413439   PPV              SCD                    Damaging   Neutral       Disease causing
  11--20   18   NGS     19    M        U         *TTN*       c.27470A\>G           p.Y9157S      ---           ---                    ---         ---         VUS              ---                    Benign     Neutral       Polymorphism
  11--20   19   NGS     20    M        U         *ANK2*      c.4373A\>G            p.E1458G      rs72544141    0.0233/0/0.0154        0.04222     CM030186    DM               LQTS                   Damaging   Deleterious   Disease causing
  11--20   19                                    *TNNT2*     c.832C\>T             p.R278C       rs121964857   0.0582/0.0227/0.461    0.04291     CM951222    DM               HCM                    Damaging   Neutral       Disease causing
  11--20   19                                    *TTN*       c.64001T\>C           p.I21334T     rs55837610    0.3873/0.026/0.2725    0.2155      ---         VUS              ---                    Benign     Deleterious   Polymorphism
  11--20   20   NGS     20    M        U         *CACNA1C*   c.5086G\>A            p.A1696T      rs370432385   0.0119/0.0/0.008       0.008678    ---         VUS              ---                    Benign     Neutral       Disease causing
  21--30   21   NGS     21    M        SUDEP     *FBN1*      c.5443G\>A            p.G1815S      ---           ---                    0.001649    ---         VUS              ---                    Damaging   Neutral       Disease causing
  21--30   21                                    *HCN4*      c.2452G\>A            p.G818S       ---           ---                    ---         ---         VUS              ---                    Damaging   Neutral       Disease causing
  21--30   22   NGS     22    M        U         *VCL*       c.510C\>T             p.T197I       rs189242810   0.0349/0.0/0.0231      0.02307     ---         VUS              ---                    Benign     Neutral       Disease causing
  21--30   23   NGS     22    H        U         *MYH6*      c.3428G\>A            p.R1143Q      rs543585784   ---                    0.0111      ---         VUS              ---                    Damaging   Neutral       Disease causing
  21--30   23                                    *TPM1*      c.451G\>A             p.A151T       ---           ---                    ---         ---         VUS              ---                    Damaging   Neutral       Disease causing
  21--30   23                                    *TTN*       c.74315T\>A           p.I24772K     rs371592971   0.0122/0.0/0.0084      0.002485    ---         VUS              ---                    Damaging   Neutral       Disease causing
  21--30   24   NGS     23    F        U         *TTN*       c.98971G\>C           p.E32991Q     rs199632397   0.0245/0.0275/0.0254   0.04170     ---         VUS              ---                    Damaging   Neutral       Polymorphism
  21--30   24                                    *TTN*       c.5993G\>A            p.R1998H      rs144135510   0.1163/0/0.0769        0.1756      ---         VUS              ---                    Damaging   Deleterious   Disease causing
  21--30   24                                    *TTN*       c.74366C\>G           p.T24789R     ---           ---                    0.002486    ---         VUS              ---                    Damaging   Deleterious   Disease causing
  21--30   25   NGS     23    M        U         *KCNQ1*     c.1343C\>G            p.P448R       rs12720449    0.0116/0.0/0.0077      0.7614      CM002332    PPV              LQTS                   Benign     Neutral       Polymorphism
  21--30   25                                    *TTN*       c.87857G\>C           p.W29286S     ---           ---                    ---         ---         PPV              ---                    Damaging   Deleterious   Disease causing
  21--30   25                                    *TTN*       c.74842T\>A           p.W24948R     ---           ---                    0.0008286   ---         VUS              ---                    Damaging   Deleterious   Disease causing
  21--30   26   NGS     23    D        SUDEP     *JUP*       c.526C\>T             p.R176W       rs368336007   0.0116/0.0/0.0077      0.006811    ---         VUS              ---                    Damaging   Deleterious   Disease causing
  21--30   26                                    *KCNH2*     c.1810G\>A            p.G604S       rs199473522   ---                    ---         CM990760    DM               LQTS                   Damaging   Deleterious   Disease causing
  21--30   27   NGS     24    M        U         *RYR2*      c.2047G\>A            p.E683K       ---           ---                    ---         ---         PPV              ---                    Damaging   Neutral       Disease causing
  21--30   27                                    *TTN*       c.29295T\>A           p.Y9766stop   ---           ---                    ---         ---         PPV              ---                    ---        Deleterious   Disease causing
  21--30   28           24    M        U         *SCN5A*     c.393-5C\>A           ---           rs368678204   0.0118/0.0/0.0078      0.01297     CS097852    PPV              LQTS                   ---        ---           ---
  21--30   28                                    *FBN1*      c.698G\>A             p.R233H       rs770140872   ---                    0.002477    ---         VUS              ---                    Damaging   Deleterious   Disease causing
  21--30   28                                    *TTN*       c.2776-4C\>A          ---           ---           ---                    0.0008331   ---         PPV              ---                    ---        ---           ---
  21--30   29   NGS     24    F        U         *KCNH2*     c.1757T\>C            p.L586P       ---           ---                    ---         ---         PPV              ---                    Damaging   Deleterious   Disease causing
  21--30   29                                    *TNNC1*     c.337G\>A             p.D113N       rs369639550   0./00227/0.0077        ---         ---         VUS              ---                    Damaging   Neutral       Disease causing
  21--30   29                                    *TTN*       c.79708C\>A           p.P26570T     rs72648227    0.0121/0/0.0083        0.1093      ---         VUS              ---                    Damaging   Deleterious   Disease causing
  21--30   29                                    *TTN*       c.39487C\>T           p.R13163C     rs72677231    0.2887/0.517/0.2136    0.2249      ---         VUS              ---                    Damaging   Deleterious   Disease causing
  21--30   29                                    *TTN*       c.8884G\>A            p.A2962T      rs376039623   0.0243/0.0/0.0167      0.0008986   ---         VUS              ---                    Damaging   Deleterious   Disease causing
  21--30   30   NGS     24    F        U         *RYR2*      c.1392C\>A            p.H464Q       ---           ---                    ---         ---         VUS              ---                    Benign     Neutral       Disease causing
  21--30   30                                    *DSG2*      c.1912G\>A            p.G638R       rs201564919   0.0242/0/0.0165        0.01244     CM109865    DM               ARVC                   Damaging   Deleterious   Disease causing
  21--30   30                                    *TTN*       c.84472C\>T           p.P28158S     rs72648247    0.2305/0.0524/0.1742   0.2484      ---         VUS              ---                    Damaging   Deleterious   Disease causing
  21--30   30                                    *TTN*       c.29781_29783dupAGA   p.E9928dup    rs368327166   ---                    ---         ---         PPV              ---                    ---        ---           Disease causing
  21--30   31   NGS     24    M        U         *PKP2*      c.1592T\>G            p.I531S       rs147240502   0.4884/0.0/0.3229      0.4722      CM102861    PPV              ARVC                   Damaging   Deleterious   Disease causing
  21--30   31                                    *HCN4*      c.3082C\>G            p.P1028A      ---           ---                    ---         ---         VUS              ---                    Benign     Neutral       Polymorphism
  21--30   31                                    *TTN*       c.85866T\>A           p.N28623K     ---           ---                    0.004143    ---         VUS              ---                    Damaging   Deleterious   Disease causing
  21--30   31                                    *TTN*       c.79896G\>C           p.M26633I     ---           ---                    0.02733     ---         VUS              ---                    Damaging   Neutral       Disease causing
  21--30   31                                    *TTN*       c.43823G\>C           p.G14608A     ---           ---                    0.02735     ---         VUS              ---                    Damaging   Deleterious   Disease causing
  21--30   32   NGS     27    M        U         *SCN4B*     c.613T\>C             p.S205P       ---           ---                    ---         ---         PPV              ---                    Damaging   Deleterious   Disease causing
  21--30   33   NGS     29    M        U         *HCN4*      c.2938G\>A            p.G980R       ---           ---                    0.003473    ---         VUS              ---                    Damaging   Neutral       Polymorphism
  21--30   33                                    *ANK2*      c.2938G\>A            p.A2948Q      rs138438183   0.0349/0.0227/0.0308   0.01898     ---         VUS              ---                    Benign     Neutral       Polymorphism
  21--30   33                                    *TTN*       c.68678T\>C           p.I22893T     ---           ---                    0.0008334   ---         VUS              ---                    Damaging   Neutral       Disease causing
  21--30   34   NGS     30    M        U         *VCL*       c.829C\>A             p.L277M       rs71579353    0.0116/0.0/0.0077      0.004126    CM062022    DM               HCM                    Benign     Neutral       Disease causing
  21--30   34                                    *TTN*       c.31720C\>T           p.P10574S     rs200992277   ---                    ---         ---         VUS              ---                    Benign     Deleterious   Polymorphism
  21--30   35   NGS     30    M        U         *ANK2*      c.4912A\>G            p.N1638D      ---           ---                    ---         ---         VUS              ---                    Benign     Neutral       Polymorphism
  21--30   35                                    *TTN*       c.88582G\>A           p.A29528T     rs376039623   0.0243/0.0/0.0167      0.006650    ---         VUS              ---                    Benign     Neutral       Disease causing
  21--30   36   NGS     30    M        U         *CASQ2*     c.730C\>T             p.H244Y       rs142036299   ---                    0.02327     ---         VUS              ---                    Damaging   Deleterious   Disease causing
  31--40   37   NGS     33    F        U         *DES*       c.935A\>C             p.D312A       rs148947510   0.0/0.2951/0.1         0.03891     CM137784    PPV              CP                     Damaging   Deleterious   Disease causing
  31--40   38   NGS     33    M        U         *MYH7*      c.4879A\>T            p.I1627F      ---           ---                    ---         ---         VUS              ---                    Benign     Neutral       Disease causing
  31--40   38                                    *TTN*       c.89786T\>C           p.I29929T     rs55660660    0.0119/0.5682/0.1932   0.09549     ---         VUS              ---                    Damaging   Deleterious   Disease causing
  31--40   38                                    *TTN*       c.81004A\>G           p.I27002V     rs139506970   0.0119/0.636/0.2166    0.07539     ---         VUS              ---                    Benign     Neutral       Disease causing
  31--40   38                                    *TTN*       c.76036A\>G           p.G19020R     rs181717727   0.024/0.6021/0.211     0.08071     ---         VUS              ---                    Damaging   Deleterious   Polymorphism
  31--40   38                                    *TTN*       c.57058G\>A           p.R922H       rs56046320    0.0116/0.9305/0.3229   0.09066     ---         VUS              ---                    Benign     Neutral       Disease causing
  31--40   38                                    *TTN*       c.2765G\>A            p.T25346A     rs188370772   0.0121/0.6282/0.2053   0.07464     ---         VUS              ---                    Benign     Deleterious   Polymorphism
  31--40   39   NGS     33    F        U         *PKP2*      c.1872G\>T            p.E624D       rs370219248   0.0/0.0227/0.0077      0.006593    ---         VUS              ---                    Benign     Neutral       Polymorphism
  31--40   39                                    *ANK2*      c.8768A\>G            p.Q2923R      rs551454026   ---                    0.09067     ---         VUS              ---                    Benign     Neutral       Polymorphism
  31--40   39                                    *TTN*       c.30515_17delAAG      p.E10172fs    rs397517549   ---                    ---         ---         PPV              ---                    ---        ---           Disease causing
  31--40   40   NGS     34    M        U         *RYR2*      c.8145G\>T            p.E2715D      rs200420897   0.0126/0.0283/0.0175   ---         ---         VUS              ---                    Damaging   Deleterious   Disease causing
  31--40   40                                    *TTN*       c.93961G\>A           p.V33889I     rs34924609    0.6481/0.1623/0.4969   0.3311      ---         VUS              ---                    Benign     Neutral       Disease causing
  31--40   41   NGS     34    M        U         *TTN*       c.47109T\>G           p.F15703L     rs370583314   0.0124/0.0/0.0086      0.004479    ---         VUS              ---                    Benign     Deleterious   Polymorphism
  31--40   41                                    *TTN*       c.52341A\>C           p.E17447D     rs575796706   ---                    0.001662    ---         VUS              ---                    Benign     Neutral       Disease causing
  31--40   41                                    *TTN*       c.45509A\>T           p.D15170V     ---           ---                    0.004973    ---         VUS              ---                    Damaging   Deleterious   Disease causing
  31--40   41                                    *JUP*       c.1717G\>T            p.D573Y       ---           ---                    ---         ---         PPV              ---                    Damaging   Deleterious   Disease causing
  31--40   42   NGS     34    F        U         *DSP*       c.4372C\>G            p.R1458G      rs28763965    0.2093/0.0908/0.1692   0.1737      CM113816    PPV              ARVC                   Damaging   Neutral       Polymorphism
  31--40   42                                    *CACNB2*    c.1180G\>A            p.V394I       rs149793143   0.0/0.0227/0.0077      0.001649    CM127056    DM               BrS                    Damaging   Neutral       Disease causing
  31--40   42                                    *SCN5A*     c.6007T\>C            p.F2004L      rs41311117    0.3107/0.0497/0.2259   0.2018      CM086913    PPV              BrS                    Damaging   Neutral       Polymorphism
  31--40   43   NGS     35    H        U         *MYBPC3*    c.3569G\>T            p.R1190L      rs117354682   0.0/0.0254/0.0082      0.005870    ---         VUS              ---                    Damaging   Deleterious   Disease causing
  31--40   43                                    *MYBPC3*    c.961G\>A             p.V321M       rs200119454   0.0471/0.0232/0.039    0.04625     CM115891    DM               DCM                    Damaging   Neutral       Disease causing
  31--40   44   S       36    M        U         *SCN5A*     c.3530C\>G            p.P1177R      ---           ---                    ---         ---         PPV              ---                    Damaging   Deleterious   Disease causing
  31--40   45   NGS     36    F        U         *KCNJ2*     c.1229A\>G            p.N410S       rs141069645   0.0233/0.0454/0.0308   0.03722     CM1313311   DM               LQTS                   Benign     Neutral       Disease causing
  31--40   46   NGS     36    F        U         *PKP2*      c.611G\>A             p.R204H       rs755215178   ---                    0.007414    ---         PBV              ---                    Benign     Neutral       Polymorphism
  31--40   46                                    *FBN1*      c.83A\>G              p.N28S        rs193922245   ---                    0.00659     ---         PBV              ---                    Benign     Neutral       Polymorphism
  31--40   47   NGS     37    M        U         *SCN5A*     c.4G\>A               p.A2T         rs199473042   ---                    0.002537    CM104269    DM               BrS                    Damaging   Neutral       Disease causing
  31--40   47                                    *SCN5A*     c.1855C\>T            p.L619F       rs199473133   0.0238/0.0/0.016       0.003699    CM030952    DM               LQTS                   Damaging   Neutral       Disease causing
  31--40   48   NGS     37    M        U         *JPH2*      c.1625G\>A            p.R542H       rs369279135   0.0/0.0304/0.0096      0.005589    ---         PBV              ---                    Benign     Neutral       Polymorphism
  31--40   49   NGS     38    M        U         *PRKAG2*    c.298G\>A             p.G100S       rs79474211    0.0814/0.0908/0.0846   0.8132      CM136115    DM               PRKAG2 syndrome        Damaging   Neutral       Disease causing
  31--40   49                                    *ACTN2*     c.1975-6C\>G          ---           rs201255023   ---                    0.1120      ---         VUS              ---                    ---        ---           ---
  31--40   49                                    *TTN*       c.77702C\>G           p.S25901C     rs202040332   0.7558/0.227/0.5767    0.1666      ---         VUS              ---                    Damaging   Deleterious   Disease causing
  31--40   49                                    *FBN1*      c.6987C\>G            p.D2329E      rs363831      0.0/0.1137/0.0385      0.06105     ---         VUS              ---                    Neutral    Neutral       Polymorphism
  31--40   49                                    *FBN1*      5672-3T\>C            ---           rs193922217   ---                    ---         ---         PPV              ---                    ---        ---           ---
  31--40   50   NGS     38    F        U         *DSP*       c.8402G\>A            p.R2801H      ---           ---                    0.0008249   ---         PPV              ---                    Damaging   Deleterious   Disease causing
  31--40   50                                    *TTN*       c.10503G\>C           p.K3501N      ---           ---                    ---         ---         VUS              ---                    Damaging   Neutral       Polymorphism
  31--40   51   NGS     38    M        U         *SCN5A*     c.4648G\>C            p.D1550H      ---           ---                    ---         ---         PPV              ---                    Damaging   Deleterious   Disease causing
  31--40   51                                    *TTN*       c.5419C\>A            p.P1807T      rs200563229   ---                    0.0008254   ---         VUS              ---                    Damaging   Deleterious   Disease causing
  31--40   52   NGS     38    M        U         *DSP*       c.3399C\>G            p.D1133E      ---           ---                    ---         ---         PPV              ---                    Damaging   Deleterious   Disease causing
  31--40   52                                    *DSC2*      c.2603C\>T            p.S868F       rs141873745   0.0/0.0227/0.0077      0.005769    ---         PBV              ---                    Benign     Neutral       Polymorphism
  31--40   53   NGS     39    M        U         *TGFB3*     c.97G\>A              p.G33S        ---           ---                    0.003295    ---         PBV              ---                    Benign     Neutral       Polymorphism
  31--40   53                                    *TTN*       c.19013C\>G           p.S6338C      ---           ---                    0.003320    ---         VUS              ---                    Damaging   Deleterious   Polymorphism
  31--40   54   NSG     39    M        U         *TTN*       c.23200G\>C           p.D7734H      ---           ---                    0.0008503   ---         VUS              ---                    Damaging   Deleterious   Disease causing
  31--40   55   S       40    M        U         *KCNH2*     c.2119T\>C            p.Y707H       ---           ---                    ---         ---         PPV              ---                    Damaging   Deleterious   Disease causing
  31--40   56   NGS     40    F        U         *FBN1*      c.4163G\>A            p.R1388H      ---           ---                    0.002477    ---         VUS              ---                    Damaging   Deleterious   Disease causing
  41--50   57   NGS     42    M        U         *MYH7*      c.5669A\>G            p.N1890S      ---           ---                    ---         ---         PPV              ---                    Damaging   Deleterious   Disease causing
  41--50   57                                    *MYH7*      c.3235C\>T            p.R1079W      rs192722540   ---                    0.004944    ---         PPV              ---                    Damaging   Deleterious   Disease causing
  41--50   57                                    *TTN*       c.21088G\>A           p.E7030K      rs72648981    0.3747/0.0261/0.2642   0.198       ---         VUS              ---                    Damaging   Deleterious   Disease causing
  41--50   57                                    *TTN*       c.583+5G\>A           ---           ---           ---                    ---         ---         VUS              ---                    ---        ---           ---
  41--50   58   NGS     42    M        U         *KCNJ2*     c.1229A\>G            p.N410S       rs141069645   0.0233/0.0454/0.0308   0.03722     CM1313311   DM               LQTS                   Benign     Neutral       Disease causing
  41--50   59   NGS     42    M        U         *CACNB2*    c.209G\>A             p.R70H        rs150722502   ---                    0.08816     ---         PPV              ---                    Damaging   Deleterious   Disease causing
  41--50   60   S       43    M        U         *RYR2*      c.12919C\>T           p.R4307C      rs200092869   0.1092/0.0/0.0745      ---         ---         VUS              ---                    Damaging   Deleterious   Polymorphism
  41--50   61   NGS     43    F        U         *KCNH2*     c.2860C\>T            p.R954C       rs141401803   ---                    0.008263    CM070176    DM               SIDS                   Damaging   Neutral       Disease causing
  41--50   62   NGS     43    M        U         *CACNA1C*   c.6169C\>T            p.R2057W      ---           ---                    ---         ---         PPV              ---                    Damaging   Deleterious   Disease causing
  41--50   62                                    *DMD*       c.6275A\>G            p.Y2092C      rs745717858   ---                    0.001141    ---         PPV              ---                    Damaging   Deleterious   Disease causing
  41--50   62                                    *CASQ2*     c.928G\>A             p.D310N       rs141314684   0.0581/0.0227/0.0461   0.06344     ---         VUS              ---                    Benign     Deleterious   Disease causing
  41--50   62                                    *PRKAG2*    c.1387G\>T            p.V463L       ---           ---                    ---         ---         PPV              ---                    Damaging   Deleterious   Disease causing
  41--50   62                                    *RYR2*      c.4465T\>C            p.1489R       rs200450676   0.0119/0.0/0.008       0.0166      ---         VUS              ---                    Damaging   Deleterious   Disease causing
  41--50   62                                    *KCNE2*     c.22A\>G              p.T8A         rs2234916     0.686/0.1135/0.4921    0.3804      CM003449    VUS              LQTS-DA                Damaging   Deleterious   Disease causing
  41--50   63   NGS     43    M        U         *MYBPC3*    c.3384G\>C            p.E1128D      rs375116558   0.0241/0.0/0.0162      0.0127      ---         VUS              ---                    Benign     Neutral       Disease causing
  41--50   64   NGS     44    M        U         *KCNH2*     c.2941A\>G            p.S981G       rs76649554    0.0116/0.0227/0.0154   0.04304     ---         VUS              ---                    Benign     Neutral       Disease causing
  41--50   65   NGS     44    M        U         *HCN4*      c.2210A\>G            p.Q737R       rs146732972   0.0/0.1365/0.0462      0.02074     ---         VUS              ---                    Damaging   Neutral       Disease causing
  41--50   65                                    *PKP2*      c.1637C\>A            p.A546E       ---           ---                    ---         ---         VUS              ---                    Benign     Neutral       Disease causing
  41--50   65                                    *CACNA1C*   c.667G\>A             p.A223T       ---           ---                    ---         ---         PPV              ---                    Damaging   Neutral       Disease causing
  41--50   66   NGS     44    M        U         *ANK2*      c.11465G\>C           p.G3822A      rs79577190    0.0/0.6809/0.2307      0.06609     ---         PBV              ---                    Benign     Neutral       Polymorphism
  41--50   66                                    *ANK2*      c.11791G\>A           p.E3931K      rs45454496    0.4186/0.0908/0.3076   0.267       CM041240    DM               CA                     Damaging   Neutral       Polymorphism
  41--50   66                                    *TTN*       c.84206T\>C           p.M28069T     ---           ---                    ---         ---         VUS              ---                    Benign     Deleterious   Polymorphism
  41--50   67   NGS     44    M        U         *MYH6*      c.3612G\>C            p.E1204D      rs751153777   ---                    ---         ---         VUS              ---                    Benign     Neutral       Disease causing
  41--50   67                                    *TTN*       c.50144-4G\>A         ---           rs369462016   0.0/0.0274/0.0085      0.002627    ---         PPV              ---                    ---        ---           ---
  41--50   68   NGS     45    M        U         *JUP*       c.475G\>T             p.V159L       ---           ---                    0.004237    CM1010258   PPV              ARVC                   Damaging   Deleterious   Disease causing
  41--50   68                                    *KCNE3*     c.46G\>A              p.A16T        ---           ---                    0.003299    ---         PBV              ---                    Benign     Neutral       Polymorphism
  41--50   68                                    *KCNE3*     c.40C\>A              p.L14M        ---           ---                    0.003299    ---         PPV              ---                    Damaging   Neutral       Disease causing
  41--50   68                                    *TTN*       c.18248C\>T           p.T6083M      ---           ---                    0.01457     ---         PBV              ---                    Benign     Neutral       Polymorphism
  41--50   69   NGS     45    M        U         *MYBPC3*    c.1786G\>A            p.G596R       rs199728019   0.0/0.0238/0.0079      0.02622     ---         VUS              ---                    Damaging   Deleterious   Disease causing
  41--50   70   NGS     46    M        U         *TTN*       c.55460C\>T           p.P18487L     rs779343098   ---                    0.001820    ---         VUS              ---                    Damaging   Deleterious   Disease causing
  41--50   71   NGS     46    M        U         *DSP*       c.1140+6T\>C          ---           rs534740669   ---                    ---         ---         VUS              ---                    ---        ---           ---
  41--50   71                                    *TTN*       c.40796G\>A           p.R13599Q     ---           ---                    0.0008291   ---         VUS              ---                    Damaging   Neutral       Polymorphism
  41--50   72   NGS     47    M        U         *CACNA1C*   c.6029G\>A            p.R2010Q      rs199776761   0.0122/0.0522/0.0249   0.01333     ---         PBV              ---                    Benign     Neutral       Polymorphism
  41--50   72                                    *DES*       c.635G\>A             p.R212Q       rs144261171   ---                    0.02059     ---         VUS              ---                    Damaging   Deleterious   Disease causing
  41--50   72                                    *TTN*       c.92737A\>G           p.I30913V     ---           ---                    ---         ---         VUS              ---                    Benign     Neutral       Polymorphism
  41--50   72                                    *TTN*       c.6950G\>A            p.R2317H      ---           ---                    0.004945    ---         VUS              ---                    Damaging   Deleterious   Disease causing
  41--50   73   NGS     48    M        U         *SCN5A*     c.1440A\>C            p.K480N       ---           ---                    0.0008383   ---         PPV              ---                    Damaging   Deleterious   Disease causing
  41--50   73                                    *TTN*       c.60754G\>C           p.A20252P     rs72646880    0.315/0.0264/0.2242    0.1961      CM1413461   PPV              SCD                    Damaging   Deleterious   Disease causing
  41--50   73                                    *TTN*       c.52846G\>A           p.V17616I     rs564621227   ---                    0.002489    ---         VUS              ---                    Benign     Neutral       Disease causing
  41--50   74   NGS     48    F        U         *MYH7*      c.3613G\>A            p.E1205K      ---           ---                    0.0008536   CM081343    DM               HCM                    Damaging   Deleterious   Disease causing
  41--50   75   NGS     48    M        U         *VCL*       c.1907A\>G            p.H636R       rs71579374    0.1279/0.0227/0.0923   0.1492      ---         VUS              ---                    Damaging   Deleterious   Disease causing
  41--50   75                                    *TTN*       c.68360A\>G           p.H22787R     ---           ---                    ---         ---         VUS              ---                    Benign     Deleterious   Disease causing
  41--50   76   NGS     48    M        U         *FBN1*      c.3463+3A\>G          ---           rs80344206    0.0/0.0227/0.0077      0.3114      ---         VUS              ---                    ---        ---           ---
  41--50   76                                    *LDB3*      c.163G\>A             p.V55I        rs3740343     0.1047/0.1135/0.1076   0.7222      ---         VUS              ---                    Benign     Neutral       Disease causing
  41--50   76                                    *TTN*       c.99430A\>C           p.N33144H     ---           ---                    0.009807    ---         VUS              ---                    Damaging   Deleterious   Disease causing
  41--50   76                                    *TTN*       c.86021G\>A           p.R28674H     rs369899675   0.012/0.0/0.0081       0.01079     ---         VUS              ---                    Damaging   Deleterious   Disease causing
  41--50   77   NGS     48    M        U         *DSG2*      c.1003A\>G            p.T335A       rs191564916   0.061/0.0/0.0419       0.05558     CM098196    PPV              ARVC                   Damaging   Neutral       Polymorphism
  41--50   77                                    *SCN5A*     c.1140+2T\>C          ---           ---           ---                    ---         ---         PPV              ---                    ---        ---           ---
  41--50   78           49    M        U         *CAV3*      c.216C\>G             p.C72W        rs116840776   0.1744/0.0681/0.1384   0.1125      CM980306    DM               MD                     Damaging   Deleterious   Disease causing
  41--50   78                                    *ANK2*      c.7372A\>T            p.S2458C      ---           ---                    ---         ---         PPV              ---                    Damaging   Deleterious   Disease causing
  41--50   78                                    *MYH6*      c.3010G\>T            p.A1004S      s143978652    0.1279/0.0227/0.0923   0.09801     CM052257    DM               DCM                    Benign     Neutral       Disease causing
  41--50   78                                    *TGFBR2*    c.1159G\>A            p.V387M       rs35766612    0.3023/0.0908/0.2307   0.1156      CM063201    DM               TAA                    Damaging   Neutral       Disease causing
  41--50   78                                    *LMNA*      c.1580G\>A            p.R527H       rs57520892    0.0116/0.0/0.0077      0.006832    CM021630    DM               Mandibular dysplasia   Benign     Deleterious   Disease causing
  41--50   79   NGS     49    M        U         *SCN5A*     c.1715C\>A            p.A572D       rs36210423    0.2388/0.0245/0.1685   0.4304      CM034060    PPV              LQTS                   Benign     Neutral       Polymorphism
  41--50   79                                    *MYBPC3*    c.2497G\>A            p.A833T       rs199865688   0.1758/0.0/0.1166      0.1682      CM032957    DM               HCM                    Damaging   Neutral       Disease causing
  41--50   79                                    *TTN*       c.58726G\>A           p.A19576T     rs183276016   0.0242/0.0261/0.0248   0.01746     ---         VUS              ---                    Damaging   Neutral       Disease causing
  41--50   79                                    *TTN*       c.89494C\>A           p.P29832T     rs373876117   0.0122/0.0/0.0084      0.01195     CM1413459   PPV              SCD                    Damaging   Deleterious   Disease causing
  41--50   79                                    *TTN*       c.17387G\>T           p.R5796L      ---           ---                    ---         ---         VUS              ---                    Damaging   Deleterious   Polymorphism
  41--50   80   NGS     50    F        U         *MYH7*      c.3382G\>A            p.A1128T      rs61741930    ---                    0.01147     ---         VUS              ---                    Damaging   Neutral       Disease causing
  41--50   80                                    *ANK2*      c.11725T\>C           p.S3909P      rs141124755   0.0116/0.2724/0.1      0.03627     ---         VUS              ---                    Benign     Neutral       Polymorphism
  41--50   80                                    *TTN*       c.87872A\>C           p.K29291T     ---           ---                    ---         ---         VUS              ---                    Benign     Deleterious   Polymorphism
  41--50   81   NGS     50    M        U         *TCAP*      c.171C\>G             p.C57W        rs369447207   0.0116/0.0/0.0077      0.003123    ---         VUS              ---                    Damaging   Deleterious   Disease causing
  41--50   81                                    *TTN*       c.27913A\>G           p.I9305V      rs376613199   0.0123/0.0/0.0085      0.02567     ---         PBV              ---                    Benign     Neutral       Polymorphism
  41--50   81                                    *TTN*       c.835C\>T             p.R279W       rs138060032   0.0116/0.0/0.0077      0.01318     ---         VUS              ---                    Damaging   Deleterious   Disease causing

NGS, Next Generation sequencing. Age is expressed in years, months (m) or days (d). Gender is expressed as Males (M) and Females (F). Autopsy is expressed as Unexplained (U), Sudden Infant Death Syndrome (SIDS) or Sudden Unexplained Death cases with Epilepsy (SUDEP). Variant nomenclature is at cDNA and Protein level. S means Sanger technology. SCD means Sudden Cardiac Death. Minor Allele Frequency (MAF) is expressed as EA/AA/ALL respectively, EA (European-American)/AA (African-American)/ALL; and Minor Alelle Frequency from The Exome Aggregation Consortium (ExAC), both are expressed in percentage. Each variant is classified as Disease Mutation (DM), Probably Pathogenic Variant (PPV), Variant of Uncertain Significance (VUS) and Probably Benign Variant (PBV). TAA means Thoracic Aortic Aneurysm. MD means Muscular Dystrophy. CA means Cardiac Arrhythmia. CP means Cardiomyopathy. LQTS-DA means Long QT Syndrome Drug-Associated.

Concerning ranges of age, the youngest cohort (between 0--10 years of age) included 28 samples (14 males -50%-, and 14 females -50%-). A total of 11 samples were screened by Sanger method, and 17 by NGS. The genetic screening by both technologies identified a total of 37 rare variants, 3 detected by Sanger method and 34 by NGS method. Four variants (10.81%) were novel. We detected 16 samples carrying at least one rare genetic variant (57.14%). Six samples (21.43%) carried variants in genes associated with ion channels and 12 samples (42.86%) carried variants in genes codifying for structural proteins. We identified 10 (35.71%) samples carrying PPV and/or DM. Finally, pathogenicity criteria classified 6 variants (16.22%) as PBV, 14 (37.84%) as VUS, 16 (43.24%) as PPV and 1 (2.7%) as DM.

The cohort between 11--21 years of age included 7 samples (5 males -71.43%-, and 2 females -28.57%-). A total of 2 samples were screened by Sanger method, 5 by NGS. The genetic screening identified a total of 10 rare variants by NGS method. The Sanger screening did not identify positive samples carrying rare variants. Of identified variants, 2 (20%) were novel. NGS method identified 4 samples (80%) carrying at least one rare variant, 3 (42.86%) carried variants in genes associated with ion channels, and 4 (57.14%) in genes codifying for structural proteins. Our classification criteria for all samples screened identified 2 (28.57%) samples carrying PPV and/or DM. Finally our classification criteria divided the 10 variants in 4 (40%) VUS, 4 (40%) PPV and 2 (20%) DM.

The cohort between 21--30 years of age included 19 samples (14 males -73.68%-, and 5 females -26.32%-). All were screened by NGS. The genetic screening identified a total of 42 rare variants. Of all them, 10 (23.81%) were novel. At least one rare variant was detected in 16 samples (84.21%), 12 (63.16%) in genes associated with ion channels, and 15 (78.95%) in genes codifying for structural proteins. Our criteria classified 9 (47.37%) as PPV and/or DM. Finally our classification criteria divided the 42 variants in 29 (69.05%) VUS, 10 (23.81%) PPV, and 3 (7.14%) DM.

The cohort between 31--40 years of age included 29 samples (20 males -68.97%-, and 9 females -31.03%-). A total of 3 samples were screened by Sanger method, 26 by NGS. Sanger screening identified 2 (66.67%) positive samples for rare variants. The genetic screening by both methods identified a total of 44 rare variants, 2 (4.5%) detected by Sanger method and 42 (95.5%) by NGS method. Of all them, 7 (15.91%) were novel. NGS method identified 18 samples (69.23%) carrying at least one rare variant, 6 (33.3%) carried variants in genes associated with ion channels, and 16 (55.2%) in genes codifying for structural proteins. Our classification criteria for all samples screened identified 13 (44.83%) samples carrying PPV and/or DM. Finally our criteria classified the 44 variants in 5 (11.36%) PBV, 22 (50%) VUS, 11 (25%) PPV and 6 (13.64%) DM.

The oldest cohort (between 41--50 years old), included 36 samples (28 males -77.78%-, and 8 females -22.22%-). A total of 8 samples were screened by Sanger method, 28 by NGS. The genetic screening by both methods identified a total of 64 rare variants, 1 (1.6%) detected by Sanger method and 63 (98.44%) by NGS method. Of all them, 13 (20.31%) were novel. NGS method identified 24 samples (85.7%) carrying at least one rare variant, 14 (50%) in genes associated with ion channels, and 20 (71.4%) in genes codifying for structural proteins. Our criteria classified 14 (38.89%) variants as PPV and/or DM. Finally our criteria classified the 64 variants in 5 (7.81%) PBV, 33 (51.56%) VUS, 17 (26.56%) PPV, and 9 (14.06%) DM.

Discussion {#sec029}
==========

In this prospective cohort we have methodically examined the etiology of natural death by performing a comprehensive investigation that includes a thorough autopsy examination and the inclusion of an extensive molecular autopsy. We have analyzed a total of 789 SD cases younger than 50 years of age. By concentrating all our cases in a same institution, a same autopsy protocol was followed, according to international forensic recommendations\[[@pone.0167358.ref001], [@pone.0167358.ref018]\].

Regarding epidemiological data, our data are in concordance with previous studies \[[@pone.0167358.ref032]\]. Thus we observed similar results in victims' mean age (39.3 years old), gender (77.19% males), progressive increase in SD prevalence from age 0 to 50, and predominance of male deaths in all ranges of age.

The primary cause of SD was cardiac -81.1%-, similar to other cohorts. In 56.87% of cases, death was labeled from coronary artery disease (CAD), either from evidence of myocardial infarction or from the identification of severe coronary stenosis, which induced ischemia-related arrhythmias \[[@pone.0167358.ref028]\]. This percentage is not much different than the one reported in other studies, which attributed nearly 40% of deaths to ischemic heart disease\[[@pone.0167358.ref033]\]. However, in other reports the percentage of CAD neared 80%. The difference in our percentage is probably due to the inclusion of population only younger than 50 years of age in our cohort. The percentage of CAD-related death increased with age and was highest in population above 40 years old, as it was expected. In 2015, Vassalini et al reported the presence of ischaemic alterations in 18.5% of a cohort of patients aged less than 40 years, while other studies have underlined higher incidences of coronary related SCD, with percentages ranging between 48 and 73% \[[@pone.0167358.ref034]--[@pone.0167358.ref038]\]. These discrepancies can be explained by the different diagnostic criteria used in sample selection and age cut-off.

Regarding the situation of death, most CAD-related SD occurred in population older than 40 years of age, and during daily activity or stress/exercise. In the young population, most cardiomyopathy-related cases died during stress/exercise. These results are in concordance with other published cohorts and well-known data about exercise being a significant risk factor for cardiac death.

Macroscopic autopsy was able to define the cause of death in most cases above age 30. However, in cases below age 30, a negative macroscopic autopsy was the most common scenario. After adding histological analysis, an additional 17% of cases were labeled as of cardiac origin, cardiomyopathy or coronary artery disease, increasing the total percentage of cardiac origin to 46%, with CAD totaling 28.5%. In the young population, the main cause of death was from cardiomyopathies and in younger than 10 years of age, inherited cardiac diseases were the primary cause, also similar to published reports \[[@pone.0167358.ref039]--[@pone.0167358.ref042]\]. Nearly 19% of our cases remained as a negative autopsy, in concordance with a recent publication of Vassalini et al \[[@pone.0167358.ref043]\]. In other reports this percentage ranges from 5% to 40%, probably related to the study cohort as well as autopsy protocols \[[@pone.0167358.ref033], [@pone.0167358.ref044]\].

In 2015, the Swiss Society of Legal Medicine created a multidisciplinary working group, clinical and molecular geneticists together with cardiologists, in the hope of harmonizing the approach to the investigation of SCD. The key points of the recommendations were (1.) the realization of a forensic autopsy procedure for all SCD victims under 40 years of age (molecular autopsy or post-mortem genetic testing), (2.) the collection and storage of adequate samples for genetic testing, (3.) communication with the families, and (4.) a multidisciplinary approach including cardiac genetic counseling\[[@pone.0167358.ref019]\]. Though, despite these recommendations and the increasing availability of NGS technology, it is yet seldom performed in most forensic centers as part of the autopsy. A current matter of argue is who should pay the genetic test. In our opinion, public health system should assume the cost of these cardiac genetic analysis due to it is well established that genetic test in cases without conclusive cause of death help to identify the cause of death in a high number of cases. In addition, these genetic tests also help clinicians in identification of genetic carriers in family members, doing prevention of SCD in relatives at risk.

Similarly, according to recent cardiology guidelines\[[@pone.0167358.ref045]\], the use of molecular autopsy should be considered in the event of an unexplained sudden cardiac death with a suspicion of inherited disease. It remains unclear when to suspect an inherited cardiac disease in most cases, as death is often the first clinical manifestation in the families. According to these same guidelines, the identification of a pathogenic variant associated with long QT syndrome or with CPVT is diagnostic of the disease. Thus, taking these data into account, the use of molecular autopsy appears mandatory in order to attempt to provide a diagnosis, which may benefit the identification of family members at risk.

For that reason, the aim of our work was to evaluate whether molecular autopsy could increase the identification of a potential etiology of death. Thus, we performed genetic investigation in all cases classified as microscopic cardiomyopathy as well as in those that remained unexplained after macro and microscopic autopsy. Thirty-two samples were reclassified as cardiomyopathies after identification of positive histological alterations. Out of these 32 samples, 19 showed histological changes consistent with a diagnosis of HCM. These results agree with several studies that report that HCM is the most prevalent cardiomyopathy associated with SCD. After genetic analysis, 33.9% of cases carried at least one PPV or DM variant, most variants remaining as VUS.

In addition, we genetically analyzed 119 samples classified as negative autopsy cases. Genetic analysis identified 41.19% of cases carrying at least one PPV or DM variant, remaining most variants as VUS. This percentage is in concordance with other genetic studies performed with NGS panels in autopsy samples \[[@pone.0167358.ref046], [@pone.0167358.ref047]\]. In post-mortem studies in which only a few genes were analyzed frequencies of detection differ between 11 to 26% \[[@pone.0167358.ref021], [@pone.0167358.ref028], [@pone.0167358.ref048]--[@pone.0167358.ref051]\]. Our percentage is higher due to the largest number of analyzed genes. Of 119 cases classified as unexplained death, around 40% carry a potentially pathogenic variant. Concretely, in our cohort, in the population younger than 31 years of age, the percentage of potentially pathogenic rare variants was 40.4%. Some reports have established that between 10% to 25% of SUD in the adult, and up to one-third in infantile and juvenile SUD, may be explained by cardiac channelopathies\[[@pone.0167358.ref008]--[@pone.0167358.ref011]\]. In most of these studies, the analysis was limited to the main genes associated with channelopathies. Our higher percentage may be due to a comprehensive genetic analysis including both genes associated with channelopathies and genes associated with cardiomyopathies, recently associated with arrhythmic pathologies without any structural alteration \[[@pone.0167358.ref052], [@pone.0167358.ref053]\]. In concordance with our results, recent studies performed in post-mortem samples using NGS technology showed percentages of rare variants potentially pathogenic in 30%-40% of samples analyzed \[[@pone.0167358.ref024]--[@pone.0167358.ref026], [@pone.0167358.ref054]--[@pone.0167358.ref058]\].

Out of 119 samples, we identified 21 DM variants in 16 cases (13.44%). Of these, 5 variants were potentially responsible for LQT, and 2 for BrS. Recent guidelines recommend the use of post-mortem genetic testing in cases with clinical evidence suggesting a diagnosis of LQTS or CPVT \[[@pone.0167358.ref029], [@pone.0167358.ref045]\]. Therefore, and according to the guidelines, a diagnosis was reached as a cause of death. In addition, 51 PPV were identified in 38 cases (31.92%). While their pathogenic role cannot be fully defined, the potential for an inherited disease makes it essential to further investigate the family members for segregation. In a recent report, Bagnall et al performed a NGS analysis in a post-mortem cohort of 490 samples died suddenly between 1--35 years old\[[@pone.0167358.ref028]\]. They identify nearly 35% of genetic variants classified as VUS and family segregation clarify the role of nearly 15% of cases concluding that autopsy investigation combined with genetic testing and family screening is the best way to identify a conclusive cause of death in cases died suddenly.

Overlapping diseases/genes {#sec030}
--------------------------

In our study we have identified samples classified as cardiomyopathies but carrying rare variants in genes encoding ion channels and/or associated proteins. Similarly, we have also identified samples classified as negative autopsy (potential channelopathy) but carrying rare variants in genes encoding structural proteins. Several studies have reported the potential pathophysiological mechanisms linking both entities in common genes. Thus, for example, *PKP2* (encoding plakophilin-2), is the main gene associated with AC and has been reported playing a pathogenic role in BrS \[[@pone.0167358.ref052], [@pone.0167358.ref053]\] despite additional studies in large cohorts should be performed to clarify this point \[[@pone.0167358.ref059]\]. In addition, alterations in *SCN5A* (encoding the sodium channel), the main gene associated with BrS, have been reported in 1--2% cases of DCM \[[@pone.0167358.ref060]\], and even AC \[[@pone.0167358.ref061]\]. In concordance with similar results from recent studies \[[@pone.0167358.ref062]\], this could suggest that a malignant arrhythmia could appear in early stage before a structural alteration is developed. However, further studies in larger cohorts should be performed to prove or refute this hypothesis.

Compound/Multigenic variants {#sec031}
----------------------------

In almost 50% of samples, more than one rare genetic variant was identified, even in the same gene in some cases. Most of these rare genetic variants are at present of unknown significance. However, whether they have a role in the final risk of sudden cardiac death is unknown. Their potential effect as genetic modifiers (either detrimental or protective) of the phenotype is well accepted, but larger and more comprehensive studies will be needed to obtain conclusive data.

Limitations {#sec032}
-----------

The first and main limitation already mentioned above is the lack of family members in order to perform a clinical-genetic segregation. The family segregation is crucial to clarify the role of identified genetic variants in each case/family. In addition, functional studies could help elucidate the pathogenic role of the variants in arrhythmogenesis but *in vitro* evidence of channel dysfunction associated with specific variants may not necessarily directly translate into a clinical phenotype in the complex biological environment of the human cardiovascular system. Finally, cases without any identified genetic variation could carry a defect in other genes not included in our NGS custom-panel.

Conclusions {#sec033}
===========

In a prospective cohort of 789 cases of natural death, younger than 50 years of age, we show that cardiac alterations are the most common cause of death, concretely coronary artery disease. While forensic investigation can determine the cause of death in most cases, nearly 19% of cases remain unanswered after a thorough autopsy investigation. The use of NGS genetic analysis has been advocated as an important complement to the investigation of death, and the incorporation of molecular autopsy in current guidelines attest to its value, according to the experts. The molecular autopsy may help identify the cause of death in a large percentage of cases remaining as negative after autopsy. In our cases without conclusive cause of death, we identified nearly 35% of PPV and nearly 15% of DM variants therefore reaching a conclusive diagnosis according to the guidelines. In our study we show that genetic analysis should be performed when there is a suspicion for an inherited cardiac disease after macroscopic or histological analysis, and when all tests have excluded a cause of death. Of notice, in SUD victims older than 30, it is important to exclude coronary disease by histology before proceeding with molecular autopsy, as this is the most common cause of death in that population. Our data show that before age 30, despite histological analysis should be performed in order to identify any microscopic alteration, the genetic analysis should be undertaken right away because the percentage of microscopic cardiac alterations is very low. In addition, even when histology identifies any microscopic cardiac alteration, the genetic results are a helpful complement of alterations identified in order to conclude cause of death. Consequently, we have proposed a simple forensic recommendation about molecular autopsy in Sudden Death cases ([Fig 6](#pone.0167358.g006){ref-type="fig"}). The evaluation of relatives should include an appropriate genetic counseling and will allow the implementation of preventive measures to the relatives at risk to prevent new cases of SCD.

![Proposal of flow chart as forensic protocol guide for Sudden Death cases.\
In cases less than 30 years old with a negative macroscopic autopsy or cases suspected of cardiomyopathy should be studied by genetics. Older cases must wait for histological analyses before be studied by genetics.](pone.0167358.g006){#pone.0167358.g006}
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